Taysha Gene Therapies, Inc. (TSHA)
Fuera de horario:
Taysha Gene Therapies, Inc.
3000 Pegasus Park Drive
Suite 1430
Dallas, TX 75247
United States
214 612 0000
https://www.tayshagtx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 52
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Sean P. Nolan | CEO & Chairman | 925.33k | N/D | 1968 |
| Dr. Sukumar Nagendran M.D. | President, Head of Research & Development and Director | 820.59k | N/D | 1967 |
| Mr. Kamran Alam CPA, M.B.A. | CFO & Corporate Secretary | 573.36k | N/D | 1978 |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations | N/D | N/D | N/D |
| Ms. Tracy M. Porter SPHR | Chief People Officer | N/D | N/D | N/D |
| Mr. Frederick Porter Ph.D. | Chief of Staff & Technical Operations Officer | N/D | N/D | N/D |
| Ms. Emily McGinnis M.P.H. | Chief Patient Advocacy & External Affairs Officer | N/D | N/D | N/D |
| Mr. Sean McAuliffe | Chief Business Officer | N/D | N/D | N/D |
| Dr. Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | N/D | N/D | N/D |
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program | N/D | N/D | N/D |
Descripción
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Gestión corporativa
La calificación ISS Governance QuickScore de Taysha Gene Therapies, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
